The upregulation of serine palmitoyltransferase Sptlc2 and ceramide synthases CerS4-6, as well as the enrichment in dihydroceramides suggests an increase in de novo SL synthesis in both NASH models. Here, SPTLC2 is linked to metabolic dysfunction-associated steatohepatitis.